IFN-γ released from immunotherapy-activated CD8+ T cells downregulates SLC3A2 and SLC7A11 expression, and increases tumor cell lipid peroxidation and ferroptosis, which ultimately improves anti-tumor efficacy of immunotherapy (114). The gene discussed is SLC3A2; the disease is neoplasm.